Advertisement
Advertisement

XERS

XERS logo

Xeris Biopharma Holdings, Inc. Common Stock

4.12
USD
+0.04
+0.88%
Apr 17, 15:59 UTC -4
Closed
exchange

After-Market

4.16

+0.04
+1.07%

Xeris Biopharma Holdings, Inc. Common Stock Profile

About

Xeris Biopharma Holdings is a biopharmaceutical company. It involved in developing and commercializing therapies for patient in endocrinology, neurology and gastroenterology. The company's principal product includes Gvoke(R), a ready-to-use liquid glucagon for the treatment of severe hypoglycemia and Keveyis(R), the first and only FDA-approved therapy for primary periodic paralysis. Xeris Biopharma Holdings, formerly known as Xeris Pharmaceuticals Inc., is headquartered in Chicago, IL.

Info & Links

CEO

John Shannon

Headquarters

1375 West Fulton Street, Suite 1300
Chicago, IL 60607, UNITED STATES

Industry

Medical Drugs

Sector

Medical

Website

www.xerispharma.com

Auditor

Ernst & Young LLP

Share holders

196

Employees

394

Xeris Biopharma Holdings, Inc. Common Stock Statistics

Valuation Measures

Market Capitalization2

640.39M

Enterprise Value

800.88M

Enterprise Value/EBITDA(ttm)

-44.46

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

3.16

Price to Book(mrq)

--

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

82.07%

Operating Margin(ttm)

-30.43%

Profit Margin(ttm)

-28.86%

Return on Equity(ttm)

--

Return on Invested Capital(ttm)

-26.82%

Return on Assets(ttm)

-17.38%

Income Statement

Revenue(ttm)

203.07M

Revenue Per Share(ttm)

1.32

Gross Profit(ttm)

166.24M

EBITDA(ttm)3

-18.01M

Net Income Available to Common(ttm)

-54.84M

Diluted EPS(ttm)

-0.45

Share Statistics

Beta (5Y Monthly)

2.61

52-Week Change

131.24%

S&P 500 52-Week Change

5.42%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

153.94M

Dividend Yield

0.00%

Float4

142.28M

% Held by Insiders

4.56%

% Held by Institutions

42.75%

Balance Sheet

Total Cash(mrq)

71.62M

Total Cash Per Share(mrq)

0.47

Total Debt(mrq)

232.11M

Total Debt/Equity(mrq)

-783.75%

Current Ratio(mrq)

1.67%

Quick Ratio(mrq)

1.29%

Book Value Per Share(mrq)

-0.20

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.25

Free Cash Flow(ytd)

-37.85M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement